Increasing number of initiatives for development of novel vaccines by government bodies, international health organizations, private sectors and public health bodies has played a crucial role in promoting the growth of meningococcal vaccines market. For instance, from April 2019, Australian Government announced Nimenrix (MenACWY vaccine) to be funded as part of the National Immunization Program (NIP) for adolescents. Moreover, novel vaccines targeting different serogroups of meningococci are receiving approvals for sales in different regions, which in turn is contributing in the growth of the market. For instance, on 30 May 2017, Pfizer Inc. received European Commission (EC) for TRUMENBA (Meningococcal Group B Vaccine). TRUMENBA aids in prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) among individuals 10 years of age and older. However, the strict storage conditions required for meningococcal vaccines, adds on to the cost, which in turn hampers the growth of the market.
Major Key Players of the Meningococcal Vaccines Market are:
GlaxoSmithKline , Sanofi, Pfizer, Serum Institute of India Pvt. Ltd, Nuron Biotech Inc., BIO-MED, Hualan Biological Engineering Inc, Walvax Biotechnology Co., Ltd. and other key players (if any) among others.
Rising incidences of meningococcal disease has considerably encouraged the development of vaccines targeting wide range of serogroups of meningococci. The highest incidence meningitis is found in the ‘meningitis belt’ of the sub-Saharan African region. For instance, in this region, major epidemics occur every 5 to 12 years, i.e. an attack rate of around 1,000 cases per 100,000 population. Global health organizations, private sector companies and government bodies across several regions are continuously promoting active immunization campaigns against meningococcal diseases. For instance, in May 2018, “Defeating meningitis by 2030” was introduced at the World Health Assembly, which aims at eradicating meningitis from all high-risk countries by 2030.
The Meningococcal Vaccines Market is segmented on the basis of Vaccine Types, Patient Type and region.
Major Vaccine Types of Meningococcal Vaccines Market covered are:
- Polysaccharide-Based Vaccines
- Quadrivalent Conjugate Vaccines
- Serogroup B Vaccines
- Others
Major Patient Types of Meningococcal Vaccines Market covered are:
- Pediatric Patients
- Adult Patients
- Others
No comments:
Post a Comment